All In Biotech

Drug Trial Radar · NCT02278315

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Feb 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31

Actual

Start

Feb 2015

Primary completion

Dec 9, 2020

Study completion Aug 10, 2022

Sponsor

Lead sponsor
Cellectar Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Oct 30, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor.

Conditions

  • Multiple Myeloma

Interventions

  • I-131-CLR1404Drug

    Single IV dose of I-131-CLR1404, increased/decreased by cohort

  • dexamethasoneDrug

    40 mg dexamethasone orally once weekly for up to 12 weeks

  • I-131-CLR1404Drug

    Multiple IV dose of I-131-CLR1404, increased/decreased by cohort

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicities (DLT)Time frame: up to 85 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Jacksonville, Florida

  • Loyola University Medical Center

    Maywood, Illinois

  • Karmanos Cancer Institute

    Detroit, Michigan

  • University of Wisconsin Hospital and Clinics

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.